Background. Without effective antiviral prophylaxis, cytomegalovirus (CMV) disease is a
common cause of morbidity and mortality after liver transplantation. In this randomized …

Cytomegalovirus disease is an important cause of morbidity following liver transplantation.
To date there has not been an effective prophylaxis for CMV disease after liver …

Cytomegalovirus (CMV)-seronegative liver transplant recipients with CMV-seropositive
donors have the greatest risk for CMV disease. We performed a randomized, controlled trial …

Background. The optimal prophylactic regimen to prevent cytomegalovirus (CMV) infection
and disease in orthotopic liver-transplant patients remains to be established. We tested …

Objective: To assess the efficacy of high-dose oral acyclovir therapy compared with
preemptive, short-course ganciclovir therapy (administered only if cytomegalovirus [CMV] …

The use of postdetection antiviral treatment of cytomegalovirus (CMV) as a strategy to
prevent infection and disease in solid-organ transplant patients has not been evaluated by …

This retrospective review compared oral valganciclovir (VGCV) 450 mg daily for 6 months
versus oral ganciclovir (GCV) 1000 mg 3 times daily for 3 months in preventing …

Despite current approaches to prophylaxis, cytomegalovirus (CMV) continues to be a
common cause of infection and disease in solid-organ-transplant patients. Thus, we …

Background. We conducted a trial of long-term ganciclovir prophylaxis for prevention of
primary cytomegalovirus (CMV) disease in CMV-seronegative liver transplant recipients with …

The efficacy and safety of valganciclovir (VGCV) for cytomegalovirus (CMV) prophylaxis in
liver transplant recipients has not been established. We retrospectively compared the …